Prognosis and complete remission rate of diffuse large B‐cell lymphoma patients in standard R‐CHOP with reduction of vincristine: A retrospective study
Background and Aims The effect of stopping or reducing the dose of vincristine in diffuse large B‐cell lymphoma (DLBCL) on the outcome and prognosis of the disease is still in doubt. The present study aimed to investigate and compare the prognosis and complete remission of two R‐CHOP treatment regim...
Uloženo v:
| Vydáno v: | Health science reports Ročník 6; číslo 12; s. e1716 - n/a |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
John Wiley & Sons, Inc
01.12.2023
John Wiley and Sons Inc Wiley |
| Témata: | |
| ISSN: | 2398-8835, 2398-8835 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Background and Aims
The effect of stopping or reducing the dose of vincristine in diffuse large B‐cell lymphoma (DLBCL) on the outcome and prognosis of the disease is still in doubt. The present study aimed to investigate and compare the prognosis and complete remission of two R‐CHOP treatment regimens with and without vincristine reduction in DLBCL patients.
Methods
This retrospective study was conducted on newly diagnosed DLBCL patients during 2018–2021. The patients were over 18 years of age, had been histologically confirmed by a pathologist, and were under treatment with R‐CHOP regimen. The clinical information of the subjects as well as the number of treatment courses were extracted from their medical records and then compared.
Results
Overall, 269 patients with DLBCL were included in this study, 15.99% of whom (n = 43) had vincristine reduction. There was no significant difference between the studied factors regarding the reduction of vincristine and the complete R‐CHOP regimen (p > 0.05). Besides, no difference was observed in the 1‐year overall survival (OS) and progression‐free survival (PFS) of the patients in the two groups treated with R‐CHOP regimen with and without vincristine reduction (p > 0.05). The complete remission rates of the patients treated with R‐CHOP regimen with and without vincristine (p > 0.05) were not different either. The results of the Cox multivariate regression showed that reducing the dose of vincristine from the R‐CHOP treatment regimen had no relationship with the 1‐year OS and PFS of the DLBCL patients (hazard ratio [HR]OS = 1.59, 95% confidence interval [CI]: 3.67–0.690, HRPFS = 1.67, 95% CI: 0.798–3.82).
Conclusion
The results of this study showed that the reduction of vincristine from the R‐CHOP regimen in the DLBCL patients was not likely to make a difference in the 1‐year OS and PFS of the patients. However, further studies are needed on the issue. |
|---|---|
| AbstractList | The effect of stopping or reducing the dose of vincristine in diffuse large B-cell lymphoma (DLBCL) on the outcome and prognosis of the disease is still in doubt. The present study aimed to investigate and compare the prognosis and complete remission of two R-CHOP treatment regimens with and without vincristine reduction in DLBCL patients.
This retrospective study was conducted on newly diagnosed DLBCL patients during 2018-2021. The patients were over 18 years of age, had been histologically confirmed by a pathologist, and were under treatment with R-CHOP regimen. The clinical information of the subjects as well as the number of treatment courses were extracted from their medical records and then compared.
Overall, 269 patients with DLBCL were included in this study, 15.99% of whom (
= 43) had vincristine reduction. There was no significant difference between the studied factors regarding the reduction of vincristine and the complete R-CHOP regimen (
> 0.05). Besides, no difference was observed in the 1-year overall survival (OS) and progression-free survival (PFS) of the patients in the two groups treated with R-CHOP regimen with and without vincristine reduction (
> 0.05). The complete remission rates of the patients treated with R-CHOP regimen with and without vincristine (
> 0.05) were not different either. The results of the Cox multivariate regression showed that reducing the dose of vincristine from the R-CHOP treatment regimen had no relationship with the 1-year OS and PFS of the DLBCL patients (hazard ratio [HR]
= 1.59, 95% confidence interval [CI]: 3.67-0.690, HR
= 1.67, 95% CI: 0.798-3.82).
The results of this study showed that the reduction of vincristine from the R-CHOP regimen in the DLBCL patients was not likely to make a difference in the 1-year OS and PFS of the patients. However, further studies are needed on the issue. Abstract Background and Aims The effect of stopping or reducing the dose of vincristine in diffuse large B‐cell lymphoma (DLBCL) on the outcome and prognosis of the disease is still in doubt. The present study aimed to investigate and compare the prognosis and complete remission of two R‐CHOP treatment regimens with and without vincristine reduction in DLBCL patients. Methods This retrospective study was conducted on newly diagnosed DLBCL patients during 2018–2021. The patients were over 18 years of age, had been histologically confirmed by a pathologist, and were under treatment with R‐CHOP regimen. The clinical information of the subjects as well as the number of treatment courses were extracted from their medical records and then compared. Results Overall, 269 patients with DLBCL were included in this study, 15.99% of whom (n = 43) had vincristine reduction. There was no significant difference between the studied factors regarding the reduction of vincristine and the complete R‐CHOP regimen (p > 0.05). Besides, no difference was observed in the 1‐year overall survival (OS) and progression‐free survival (PFS) of the patients in the two groups treated with R‐CHOP regimen with and without vincristine reduction (p > 0.05). The complete remission rates of the patients treated with R‐CHOP regimen with and without vincristine (p > 0.05) were not different either. The results of the Cox multivariate regression showed that reducing the dose of vincristine from the R‐CHOP treatment regimen had no relationship with the 1‐year OS and PFS of the DLBCL patients (hazard ratio [HR]OS = 1.59, 95% confidence interval [CI]: 3.67–0.690, HRPFS = 1.67, 95% CI: 0.798–3.82). Conclusion The results of this study showed that the reduction of vincristine from the R‐CHOP regimen in the DLBCL patients was not likely to make a difference in the 1‐year OS and PFS of the patients. However, further studies are needed on the issue. The effect of stopping or reducing the dose of vincristine in diffuse large B-cell lymphoma (DLBCL) on the outcome and prognosis of the disease is still in doubt. The present study aimed to investigate and compare the prognosis and complete remission of two R-CHOP treatment regimens with and without vincristine reduction in DLBCL patients.Background and AimsThe effect of stopping or reducing the dose of vincristine in diffuse large B-cell lymphoma (DLBCL) on the outcome and prognosis of the disease is still in doubt. The present study aimed to investigate and compare the prognosis and complete remission of two R-CHOP treatment regimens with and without vincristine reduction in DLBCL patients.This retrospective study was conducted on newly diagnosed DLBCL patients during 2018-2021. The patients were over 18 years of age, had been histologically confirmed by a pathologist, and were under treatment with R-CHOP regimen. The clinical information of the subjects as well as the number of treatment courses were extracted from their medical records and then compared.MethodsThis retrospective study was conducted on newly diagnosed DLBCL patients during 2018-2021. The patients were over 18 years of age, had been histologically confirmed by a pathologist, and were under treatment with R-CHOP regimen. The clinical information of the subjects as well as the number of treatment courses were extracted from their medical records and then compared.Overall, 269 patients with DLBCL were included in this study, 15.99% of whom (n = 43) had vincristine reduction. There was no significant difference between the studied factors regarding the reduction of vincristine and the complete R-CHOP regimen (p > 0.05). Besides, no difference was observed in the 1-year overall survival (OS) and progression-free survival (PFS) of the patients in the two groups treated with R-CHOP regimen with and without vincristine reduction (p > 0.05). The complete remission rates of the patients treated with R-CHOP regimen with and without vincristine (p > 0.05) were not different either. The results of the Cox multivariate regression showed that reducing the dose of vincristine from the R-CHOP treatment regimen had no relationship with the 1-year OS and PFS of the DLBCL patients (hazard ratio [HR]OS = 1.59, 95% confidence interval [CI]: 3.67-0.690, HRPFS = 1.67, 95% CI: 0.798-3.82).ResultsOverall, 269 patients with DLBCL were included in this study, 15.99% of whom (n = 43) had vincristine reduction. There was no significant difference between the studied factors regarding the reduction of vincristine and the complete R-CHOP regimen (p > 0.05). Besides, no difference was observed in the 1-year overall survival (OS) and progression-free survival (PFS) of the patients in the two groups treated with R-CHOP regimen with and without vincristine reduction (p > 0.05). The complete remission rates of the patients treated with R-CHOP regimen with and without vincristine (p > 0.05) were not different either. The results of the Cox multivariate regression showed that reducing the dose of vincristine from the R-CHOP treatment regimen had no relationship with the 1-year OS and PFS of the DLBCL patients (hazard ratio [HR]OS = 1.59, 95% confidence interval [CI]: 3.67-0.690, HRPFS = 1.67, 95% CI: 0.798-3.82).The results of this study showed that the reduction of vincristine from the R-CHOP regimen in the DLBCL patients was not likely to make a difference in the 1-year OS and PFS of the patients. However, further studies are needed on the issue.ConclusionThe results of this study showed that the reduction of vincristine from the R-CHOP regimen in the DLBCL patients was not likely to make a difference in the 1-year OS and PFS of the patients. However, further studies are needed on the issue. Background and AimsThe effect of stopping or reducing the dose of vincristine in diffuse large B-cell lymphoma (DLBCL) on the outcome and prognosis of the disease is still in doubt. The present study aimed to investigate and compare the prognosis and complete remission of two R-CHOP treatment regimens with and without vincristine reduction in DLBCL patients.MethodsThis retrospective study was conducted on newly diagnosed DLBCL patients during 2018–2021. The patients were over 18 years of age, had been histologically confirmed by a pathologist, and were under treatment with R-CHOP regimen. The clinical information of the subjects as well as the number of treatment courses were extracted from their medical records and then compared.ResultsOverall, 269 patients with DLBCL were included in this study, 15.99% of whom (n = 43) had vincristine reduction. There was no significant difference between the studied factors regarding the reduction of vincristine and the complete R-CHOP regimen (p > 0.05). Besides, no difference was observed in the 1-year overall survival (OS) and progression-free survival (PFS) of the patients in the two groups treated with R-CHOP regimen with and without vincristine reduction (p > 0.05). The complete remission rates of the patients treated with R-CHOP regimen with and without vincristine (p > 0.05) were not different either. The results of the Cox multivariate regression showed that reducing the dose of vincristine from the R-CHOP treatment regimen had no relationship with the 1-year OS and PFS of the DLBCL patients (hazard ratio [HR]OS = 1.59, 95% confidence interval [CI]: 3.67–0.690, HRPFS = 1.67, 95% CI: 0.798–3.82).ConclusionThe results of this study showed that the reduction of vincristine from the R-CHOP regimen in the DLBCL patients was not likely to make a difference in the 1-year OS and PFS of the patients. However, further studies are needed on the issue. Background and Aims The effect of stopping or reducing the dose of vincristine in diffuse large B‐cell lymphoma (DLBCL) on the outcome and prognosis of the disease is still in doubt. The present study aimed to investigate and compare the prognosis and complete remission of two R‐CHOP treatment regimens with and without vincristine reduction in DLBCL patients. Methods This retrospective study was conducted on newly diagnosed DLBCL patients during 2018–2021. The patients were over 18 years of age, had been histologically confirmed by a pathologist, and were under treatment with R‐CHOP regimen. The clinical information of the subjects as well as the number of treatment courses were extracted from their medical records and then compared. Results Overall, 269 patients with DLBCL were included in this study, 15.99% of whom (n = 43) had vincristine reduction. There was no significant difference between the studied factors regarding the reduction of vincristine and the complete R‐CHOP regimen (p > 0.05). Besides, no difference was observed in the 1‐year overall survival (OS) and progression‐free survival (PFS) of the patients in the two groups treated with R‐CHOP regimen with and without vincristine reduction (p > 0.05). The complete remission rates of the patients treated with R‐CHOP regimen with and without vincristine (p > 0.05) were not different either. The results of the Cox multivariate regression showed that reducing the dose of vincristine from the R‐CHOP treatment regimen had no relationship with the 1‐year OS and PFS of the DLBCL patients (hazard ratio [HR]OS = 1.59, 95% confidence interval [CI]: 3.67–0.690, HRPFS = 1.67, 95% CI: 0.798–3.82). Conclusion The results of this study showed that the reduction of vincristine from the R‐CHOP regimen in the DLBCL patients was not likely to make a difference in the 1‐year OS and PFS of the patients. However, further studies are needed on the issue. |
| Author | Riasi, Fatemeh Shakeri, Mohammad T. Ataei Azimi, Sajjad Allahyari, Abolghasem Moeini Nodeh, Mohammad Kamandi, Mostafa |
| AuthorAffiliation | 3 Department of Biostatistics, School of Health Mashhad University of Medical Sciences Mashhad Iran 1 Department of Internal Medicine, Faculty of Medicine Mashhad University of Medical Sciences Mashhad Iran 2 Faculty of Medicine Mashhad University of Medical Sciences Mashhad Iran |
| AuthorAffiliation_xml | – name: 3 Department of Biostatistics, School of Health Mashhad University of Medical Sciences Mashhad Iran – name: 1 Department of Internal Medicine, Faculty of Medicine Mashhad University of Medical Sciences Mashhad Iran – name: 2 Faculty of Medicine Mashhad University of Medical Sciences Mashhad Iran |
| Author_xml | – sequence: 1 givenname: Fatemeh surname: Riasi fullname: Riasi, Fatemeh organization: Mashhad University of Medical Sciences – sequence: 2 givenname: Sajjad surname: Ataei Azimi fullname: Ataei Azimi, Sajjad organization: Mashhad University of Medical Sciences – sequence: 3 givenname: Abolghasem surname: Allahyari fullname: Allahyari, Abolghasem organization: Mashhad University of Medical Sciences – sequence: 4 givenname: Mohammad surname: Moeini Nodeh fullname: Moeini Nodeh, Mohammad organization: Mashhad University of Medical Sciences – sequence: 5 givenname: Mohammad T. surname: Shakeri fullname: Shakeri, Mohammad T. organization: Mashhad University of Medical Sciences – sequence: 6 givenname: Mostafa orcidid: 0000-0001-8518-0108 surname: Kamandi fullname: Kamandi, Mostafa email: kamandim@mums.ac.ir organization: Mashhad University of Medical Sciences |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38033714$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1ks1u1DAQgC1URMvSAy-ALHGBw7a2E8c2F1RWwFaq1KrA2XJsZ9erxA52stXeeATuvB1PgtMtVYvEyT_z-fNoZp6DAx-8BeAlRicYIXK6TpGcYIarJ-CIFILPOS_owYP9IThOaYMyi0hJuXgGDguOioLh8gj8uoph5UNyCSpvoA5d39rBwmg7l5ILHkaVj6GBxjXNmCxsVVxZ-OH3j5_ati1sd12_Dp2CvRqc9UOCzsM0ZJmKBl5nbLG8vII3blhnqRn1MEmzb-u8ji4Nztt38CzHhhhSb3N8a7NgNLsX4Gmj2mSP79YZ-Pbp49fFcn5x-fl8cXYx17Rg1RyjmlQ153WtmGUcNZxiIYhlShUUK1LXTCMlDDKYV9aQhpaVKWtLmoJSzapiBs73XhPURvbRdSruZFBO3l6EuJIqDk63VpZYT6-1ZiUr82c1KZHQhIqScKaFya73e1c_1p01OlckqvaR9HHEu7Vcha3EqOKlyP2agTd3hhi-jzYNMndiKrXyNoxJEi4qjjBlLKOv_0E3YYw-10oSgagQCAmSqVcPU7rP5e8QZODtHtC5Ayna5h7BSE4zJqcZk9OMZfZ0z9641u7-D8rll2ty--IPnovWLg |
| Cites_doi | 10.1038/bjc.2015.94 10.3960/jslrt.51.1 10.1016/S0140-6736(07)61602-X 10.1016/j.neulet.2014.10.014 10.1007/s00432-018-2771-9 10.1016/S1470-2045(06)70664-7 10.1016/j.clml.2022.06.013 10.1007/s00277-018-3437-z 10.1186/1756-9966-28-116 10.1212/01.WNL.0000154642.45474.28 10.1016/j.clml.2020.12.017 10.1517/17425255.2014.885016 10.1056/NEJMoa011795 10.1007/s00277-010-0956-7 10.1182/blood-2010-03-276246 10.1007/s12185-020-02984-w 10.1002/cncr.20956 10.1371/journal.pone.0123978 10.1016/S1470-2045(11)70235-2 |
| ContentType | Journal Article |
| Copyright | 2023 The Authors. published by Wiley Periodicals LLC. 2023 The Authors. Health Science Reports published by Wiley Periodicals LLC. 2023. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: 2023 The Authors. published by Wiley Periodicals LLC. – notice: 2023 The Authors. Health Science Reports published by Wiley Periodicals LLC. – notice: 2023. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | 24P AAYXX CITATION NPM 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 5PM DOA |
| DOI | 10.1002/hsr2.1716 |
| DatabaseName | Wiley Online Library Open Access CrossRef PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni) Proquest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest One Health & Nursing ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete ProQuest Health & Medical Research Collection Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: PIMPY name: ProQuest Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | RIASI et al |
| EISSN | 2398-8835 |
| EndPage | n/a |
| ExternalDocumentID | oai_doaj_org_article_41c546dcc7474e78b2409c2594287c9d PMC10684988 38033714 10_1002_hsr2_1716 HSR21716 |
| Genre | researchArticle Journal Article |
| GrantInformation_xml | – fundername: Mashhad University of Medical Sciences – fundername: ; |
| GroupedDBID | 0R~ 1OC 24P 53G 7X7 8FI 8FJ AAMMB ABUWG ACCMX ACXQS ADBBV ADKYN ADZMN AEFGJ AFKRA AGXDD AIDQK AIDYY ALMA_UNASSIGNED_HOLDINGS ALUQN AOIJS AVUZU BCNDV BENPR BPHCQ BVXVI CCPQU EBS EJD EMOBN FYUFA GROUPED_DOAJ HMCUK HYE IAO IHR INH ITC M~E OK1 PHGZM PHGZT PIMPY PQQKQ PROAC PUEGO RPM UKHRP WIN AAYXX AFFHD CITATION AAHHS ACCFJ ADZOD AEEZP AEQDE AIWBW AJBDE ALIPV NPM 3V. 7XB 8FK AZQEC DWQXO K9. PJZUB PKEHL PPXIY PQEST PQUKI 7X8 5PM |
| ID | FETCH-LOGICAL-c5376-10b26b88bba7e780f851992e7aa351a2bb7c0a9d0d186ed2f546d4be2f355c763 |
| IEDL.DBID | 7X7 |
| ISICitedReferencesCount | 0 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001111656100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2398-8835 |
| IngestDate | Fri Oct 03 12:45:28 EDT 2025 Tue Nov 04 02:06:27 EST 2025 Thu Oct 02 05:55:13 EDT 2025 Tue Oct 07 07:06:08 EDT 2025 Wed Feb 19 02:07:04 EST 2025 Sat Nov 29 04:05:25 EST 2025 Sun Sep 21 06:22:36 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 12 |
| Keywords | DLBCL R‐CHOP vincristine prognosis |
| Language | English |
| License | Attribution-NonCommercial 2023 The Authors. Health Science Reports published by Wiley Periodicals LLC. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5376-10b26b88bba7e780f851992e7aa351a2bb7c0a9d0d186ed2f546d4be2f355c763 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0001-8518-0108 |
| OpenAccessLink | https://www.proquest.com/docview/2905990092?pq-origsite=%requestingapplication% |
| PMID | 38033714 |
| PQID | 2905990092 |
| PQPubID | 4370312 |
| PageCount | 6 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_41c546dcc7474e78b2409c2594287c9d pubmedcentral_primary_oai_pubmedcentral_nih_gov_10684988 proquest_miscellaneous_2896801577 proquest_journals_2905990092 pubmed_primary_38033714 crossref_primary_10_1002_hsr2_1716 wiley_primary_10_1002_hsr2_1716_HSR21716 |
| PublicationCentury | 2000 |
| PublicationDate | December 2023 |
| PublicationDateYYYYMMDD | 2023-12-01 |
| PublicationDate_xml | – month: 12 year: 2023 text: December 2023 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Hoboken |
| PublicationTitle | Health science reports |
| PublicationTitleAlternate | Health Sci Rep |
| PublicationYear | 2023 |
| Publisher | John Wiley & Sons, Inc John Wiley and Sons Inc Wiley |
| Publisher_xml | – name: John Wiley & Sons, Inc – name: John Wiley and Sons Inc – name: Wiley |
| References | 2010; 89 2021; 21 1990 2007; 370 2010; 116 2005; 103 2015; 596 2015; 112 2011; 51 2015; 10 2006; 7 2002; 346 2005; 64 2011; 12 2020; 112 2022; 22 2018; 97 2014; 6 2019; 145 2014; 10 2009; 28 e_1_2_11_10_1 e_1_2_11_21_1 e_1_2_11_20_1 e_1_2_11_14_1 e_1_2_11_13_1 e_1_2_11_9_1 Okada N (e_1_2_11_11_1) 2014; 6 e_1_2_11_12_1 e_1_2_11_8_1 e_1_2_11_22_1 e_1_2_11_7_1 e_1_2_11_18_1 e_1_2_11_6_1 e_1_2_11_17_1 e_1_2_11_5_1 e_1_2_11_16_1 e_1_2_11_4_1 e_1_2_11_15_1 e_1_2_11_3_1 e_1_2_11_2_1 e_1_2_11_19_1 |
| References_xml | – volume: 116 start-page: 2040 issue: 12 year: 2010 end-page: 2045 article-title: Long‐term outcome of patients in the LNH‐98.5 trial, the first randomized study comparing rituximab‐CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte publication-title: Blood – volume: 346 start-page: 235 issue: 4 year: 2002 end-page: 242 article-title: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large‐B‐cell lymphoma publication-title: N Engl J Med – volume: 97 start-page: 2129 year: 2018 end-page: 2135 article-title: Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome? publication-title: Ann Hematol – volume: 10 issue: 4 year: 2015 article-title: Differential impact of relative dose‐intensity reductions in diffuse large B‐cell lymphoma treated with R‐CHOP21 or R‐CHOP14 publication-title: PLoS One – volume: 103 start-page: 1644 issue: 8 year: 2005 end-page: 1651 article-title: Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B‐cell lymphoma publication-title: Cancer – volume: 112 start-page: 1575 issue: 9 year: 2015 end-page: 1584 article-title: Lymphoma incidence, survival and prevalence 2004–2014: sub‐type analyses from the UK's Haematological Malignancy Research Network publication-title: Br J Cancer – volume: 6 start-page: 252 issue: 4 year: 2014 article-title: Risk factors for early‐onset peripheral neuropathy caused by vincristine in patients with a first administration of R‐CHOP or R‐CHOP‐like chemotherapy publication-title: J Clin Med Res – volume: 22 start-page: e947 issue: 10 year: 2022 end-page: e957 article-title: R‐CHOP vs DA‐EPOCH‐R for double‐expressor lymphoma: a University of California hematologic malignancies consortium retrospective analysis publication-title: Clin Lymphoma Myeloma Leuk – volume: 12 start-page: 1013 issue: 11 year: 2011 end-page: 1022 article-title: CHOP‐like chemotherapy with or without rituximab in young patients with good‐prognosis diffuse large‐B‐cell lymphoma: 6‐year results of an open‐label randomised study of the MabThera International Trial (MInT) group publication-title: Lancet Oncol – volume: 596 start-page: 90 year: 2015 end-page: 107 article-title: Chemotherapy‐induced peripheral neuropathy: what do we know about mechanisms? publication-title: Neurosci Lett – volume: 145 start-page: 117 year: 2019 end-page: 127 article-title: DA‐EPOCH‐R improves the outcome over that of R‐CHOP regimen for DLBCL patients below 60 years, GCB phenotype, and those with high‐risk IPI, but not for double expressor lymphoma publication-title: J Cancer Res Clin Oncol – volume: 112 start-page: 807 year: 2020 end-page: 816 article-title: Dose‐adjusted EPOCH with or without rituximab for aggressive lymphoma patients: real world data publication-title: Int J Hematol – volume: 51 start-page: 1 issue: 1 year: 2011 end-page: 5 article-title: Importance of relative dose intensity in chemotherapy for diffuse large B‐cell lymphoma publication-title: J Clin Exp Hematop – volume: 10 start-page: 483 issue: 3 year: 2014 end-page: 494 article-title: Pharmacokinetic evaluation of vincristine for the treatment of lymphoid malignancies publication-title: Expert Opin Drug Metab Toxicol – volume: 89 start-page: 897 year: 2010 end-page: 904 article-title: Importance of maintaining the relative dose intensity of CHOP‐like regimens combined with rituximab in patients with diffuse large B‐cell lymphoma publication-title: Ann Hematol – volume: 28 start-page: 1 year: 2009 end-page: 6 article-title: Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R‐CHOP) on survival in diffuse large B‐cell lymphoma publication-title: J Exp Clin Cancer Res – volume: 21 start-page: 162 issue: 3 year: 2021 end-page: 169 article-title: Impact of omission/reduction of vincristine from R‐CHOP in treatment of DLBCL publication-title: Clin Lymphoma Myeloma Leuk – year: 1990 – volume: 370 start-page: 1453 issue: 9596 year: 2007 end-page: 1457 article-title: The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies publication-title: Lancet – volume: 7 start-page: 379 issue: 5 year: 2006 end-page: 391 article-title: CHOP‐like chemotherapy plus rituximab versus CHOP‐like chemotherapy alone in young patients with good‐prognosis diffuse large‐B‐cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) group publication-title: Lancet Oncol – volume: 64 start-page: 1076 issue: 6 year: 2005 end-page: 1077 article-title: Dose‐related vincristine‐induced peripheral neuropathy with unexpected off‐therapy worsening publication-title: Neurology – ident: e_1_2_11_2_1 doi: 10.1038/bjc.2015.94 – ident: e_1_2_11_15_1 doi: 10.3960/jslrt.51.1 – ident: e_1_2_11_19_1 doi: 10.1016/S0140-6736(07)61602-X – ident: e_1_2_11_20_1 doi: 10.1016/j.neulet.2014.10.014 – ident: e_1_2_11_22_1 doi: 10.1007/s00432-018-2771-9 – ident: e_1_2_11_5_1 doi: 10.1016/S1470-2045(06)70664-7 – ident: e_1_2_11_7_1 doi: 10.1016/j.clml.2022.06.013 – ident: e_1_2_11_10_1 doi: 10.1007/s00277-018-3437-z – ident: e_1_2_11_12_1 doi: 10.1186/1756-9966-28-116 – volume: 6 start-page: 252 issue: 4 year: 2014 ident: e_1_2_11_11_1 article-title: Risk factors for early‐onset peripheral neuropathy caused by vincristine in patients with a first administration of R‐CHOP or R‐CHOP‐like chemotherapy publication-title: J Clin Med Res – ident: e_1_2_11_17_1 doi: 10.1212/01.WNL.0000154642.45474.28 – ident: e_1_2_11_18_1 doi: 10.1016/j.clml.2020.12.017 – ident: e_1_2_11_21_1 doi: 10.1517/17425255.2014.885016 – ident: e_1_2_11_16_1 doi: 10.1056/NEJMoa011795 – ident: e_1_2_11_13_1 doi: 10.1007/s00277-010-0956-7 – ident: e_1_2_11_3_1 doi: 10.1182/blood-2010-03-276246 – ident: e_1_2_11_8_1 – ident: e_1_2_11_6_1 doi: 10.1007/s12185-020-02984-w – ident: e_1_2_11_9_1 doi: 10.1002/cncr.20956 – ident: e_1_2_11_14_1 doi: 10.1371/journal.pone.0123978 – ident: e_1_2_11_4_1 doi: 10.1016/S1470-2045(11)70235-2 |
| SSID | ssj0002024589 |
| Score | 2.2394378 |
| Snippet | Background and Aims
The effect of stopping or reducing the dose of vincristine in diffuse large B‐cell lymphoma (DLBCL) on the outcome and prognosis of the... The effect of stopping or reducing the dose of vincristine in diffuse large B-cell lymphoma (DLBCL) on the outcome and prognosis of the disease is still in... Background and AimsThe effect of stopping or reducing the dose of vincristine in diffuse large B-cell lymphoma (DLBCL) on the outcome and prognosis of the... Abstract Background and Aims The effect of stopping or reducing the dose of vincristine in diffuse large B‐cell lymphoma (DLBCL) on the outcome and prognosis... |
| SourceID | doaj pubmedcentral proquest pubmed crossref wiley |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | e1716 |
| SubjectTerms | Age Chemotherapy Dehydrogenases DLBCL Drug dosages Hematology Lymphoma Medical prognosis Medical records Original Research Peripheral neuropathy prognosis Radiation Remission (Medicine) R‐CHOP Survival analysis Toxicity vincristine |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrZ1Lb9QwEMdHqEKIC-JNoCCDOHAJzTpOYnNrK6o9QFmVh3qL_IqaqiQo2a3EjY_AnW_HJ2HGSVa7AsSFWxRbluMZ23_bk58BnqfK5EZbF_NKpLGwhY8V6pI4d5WyQnluAkrp05vi-FienqrFxlVfFBM24IGHhtsTM5uJ3FmLulf4QhqcgpRF0U5a3ypHo29SqI3F1Hk4XuMik2pCCSV876zv-Etiw2xNQIHT_ydx-XuM5KZ2DZPP0U24MapGtj_U9hZc8c1tuPZ2PBe_Az8WXUsRc3XPdONYiBNHNcw6us2N9sMYESFYWzG6EGXVe3ZBEeDs4Oe377R1zy6-olXbz5qNnNWe1Q2bthnYCWY7nL9bMNq1xULdgJyl8i7rxoZxovGv2D6mLbt2-nuTBXbtXfh49PrD4Twer12ILbFdcGA2PDdSGqMLbPCkQlGmFPeF1mk209yYwiZaucTNZO4dr8g-wnheoXaxOF7dg52mbfwDYCjGjMhSFCXOCeky7Sos0uEqKJPOqlkEzyZblF8GukY5cJR5SQYryWARHJCV1hkIiB1eoJuUo5uU_3KTCHYnG5djL-1LrohOQ9ipCJ6uk9Ew1PK68e0K80iV4yyeFUUE9weXWNcklUlKxMMI5JazbFV1O6WpzwLDG1fiUigpI3gR_Orvn1_O359wenj4P9rhEVzHvpEOATm7sLPsVv4xXLWXy7rvnoRO9AtDVSU4 priority: 102 providerName: Directory of Open Access Journals – databaseName: Wiley Online Library Open Access dbid: 24P link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpZ1Lb9QwEMdHpSDEhfcjUJBBHLiEbhwnseHUVlQ9QFmVh3qL_ApdqSQo2a3EjY_AnW_HJ2HGecAKkJC4RbFjOfaM8_fY-RngcapMbrR1Ma9EGgtb-FihLolzVykrlOcmoJTevywOD-XxsZpvwPPxX5ieDzEF3MgzwnhNDq5Nt_0TGnrStfwpwV7OwfkkSQsyaS7mU4CF06JiOAKPEHexRKkxkoVmfHt6eu17FLD9f9Kav2-Z_FXKhm_R_pX_eourcHmQoGynt5lrsOHr63Dx1bDIfgO-zduGtt8tOqZrx8Kmc5TWrKWj4Si4xggvwZqK0ekqq86zU9pOzna_f_lK6wDs9DOaSPNRswHa2rFFzcaYBTvCbHsHr-eMQsBYqOv5tVTe2aK2YdCp_TO2g2nLthl_BWUBhHsT3u2_eLt3EA9nOMSWQDE4yhueGymN0YUv5KxChacU94XWaZZobkxhZ1q5mUtk7h2vMpE7YTyvUAhZHPxuwWbd1P4OMFR2RmQpKhznhHSZdhUW6XBKlUlnVRLBo7Eny089qqPsocy8pGYuqZkj2KU-njIQXTvcaNoP5eCspUgsVcNanGsJrLVB2aMsThRpfmmVi2BrtJBycPmu5IpQN8SwiuDhlIwdQy2va9-sMI9UOUqCrCgiuN0b1FSTVM5SwidGINdMba2q6yn14iQAwXFaL4WSMoInwdb-_vrlwZsjThd3_z3rPbiEvpT2e3i2YHPZrvx9uGDPlouufRCc7gdt5TN1 priority: 102 providerName: Wiley-Blackwell |
| Title | Prognosis and complete remission rate of diffuse large B‐cell lymphoma patients in standard R‐CHOP with reduction of vincristine: A retrospective study |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fhsr2.1716 https://www.ncbi.nlm.nih.gov/pubmed/38033714 https://www.proquest.com/docview/2905990092 https://www.proquest.com/docview/2896801577 https://pubmed.ncbi.nlm.nih.gov/PMC10684988 https://doaj.org/article/41c546dcc7474e78b2409c2594287c9d |
| Volume | 6 |
| WOSCitedRecordID | wos001111656100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2398-8835 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002024589 issn: 2398-8835 databaseCode: DOA dateStart: 20180101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2398-8835 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002024589 issn: 2398-8835 databaseCode: M~E dateStart: 20180101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2398-8835 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002024589 issn: 2398-8835 databaseCode: 7X7 dateStart: 20180101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2398-8835 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002024589 issn: 2398-8835 databaseCode: BENPR dateStart: 20180101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Publicly Available Content Database customDbUrl: eissn: 2398-8835 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002024589 issn: 2398-8835 databaseCode: PIMPY dateStart: 20180101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVWIB databaseName: Wiley Online Library customDbUrl: eissn: 2398-8835 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002024589 issn: 2398-8835 databaseCode: WIN dateStart: 20170101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell – providerCode: PRVWIB databaseName: Wiley Online Library Open Access customDbUrl: eissn: 2398-8835 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002024589 issn: 2398-8835 databaseCode: 24P dateStart: 20170101 isFulltext: true titleUrlDefault: https://authorservices.wiley.com/open-science/open-access/browse-journals.html providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9NAEB7RFiEuvB-GEi2IAxfTZP3a5YKaqlUq0WCFV3qyvA_TSMUudlKJX8LfZWZtByIeFy5R7LVWY8_s-JvZ8TcAzwOpYpVr4_MiDPxQJ9aXiEv82BRSh9Jy5aiUPr5JplMxn8u0S7g1XVll7xOdozaVphz5HpfEJEIUQa8vvvrUNYp2V7sWGluwQ22zyc6TebLOsXDaVxSyJxQa8r2zpuYviSFm4zXk2Pr_BDF_r5T8FcG6V9DRzf8V_hbc6MAn22-t5TZcseUduHbSba_fhe9pXVHh3aJheWmYKzdHUM1qagpHaTVGxBKsKhj1VVk1lp1TITkb-5T_Z-ff0DSqLznryFobtihZn6tgM_9g8jZllPjFCU3LWktzXS5K7VxNaV-xfRxb1lX_AShz9Lf34MPR4fuDid91bvA10cOgb1c8VkIolSc2EcMCcZ2U3CZ5HkSjnCuV6GEuzdCMRGwNL6IwNqGyvED4o9Hl3YftsirtQ2CI51QYBYhrjAmFiXJT4JQGA6lIGC1HHjzrFZldtAQdWUvFzDPSdkba9mBMKl5fQJza7kRVf866JZqFI01iaI0RVohSKwQ7UmN4SFGllsaD3V65WbfQm-ynZj14uh5GpdBzz0tbrfAaIWMEAlGSePCgtae1JIEYBkSa6IHYsLQNUTdHysWZowHHYF6EUggPXjij_PvtZ5N3M05_Hv37Fh7DdVwyQVutswvby3pln8BVfblcNPUAtniYDtwKc79iADvjw2k6G7hEBh6lxyfpKR59Op7-AKMaN6M |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Zb9QwEB6VgoAX7iNQwCCQeEmbdS4bCaG2UG3V7bJqC9q3ND5CVypJSXaL-kv4F_xGZnIsrDje-sBbFFuW7XwznhlPvgF47ksVqVQbl2eB7wY6tq5Eu8SNTCZ1IC1XNZXSx0E8HIrxWI6W4Hv3LwylVXY6sVbUptAUI1_jkphEiCLozckXl6pG0e1qV0KjgcWOPfuKLlv1evstft8XnG-9O9jsu21VAVcTdQnqHcUjJYRSaWxj4WVoc0jJbZymfthLuVKx9lJpPNMTkTU8C4PIBMryDI9mjeKI416Ai6jHY3L24nE8j-lwuscUsiMw8vjaUVXyVWKkWTj26uoAfzJpf8_M_NViro-8rev_22bdgGutcc3WG2m4CUs2vwWXd9v0gdvwbVQWlFg4qViaG1an06PTwEoqekdhQ0bEGazIGNWNmVWWHVOiPNtw6X6DHZ8h9IvPKWvJaCs2yVkXi2F77mb__YhRYBsHNA0rL411Osl1rUpz-4qtY9u0LLofXFlN73sHPpzLttyF5bzI7X1gaK-qIPTRbjMmECZMTYZDGnQUQ2G07DnwrANOctIQkCQN1TRPCF0JocuBDYLUvANxhtcvivJT0qqgJOhpmobW6EEGOGuFxpzU6P6S16ylcWClA1PSKrIq-YkkB57Om_Gj0L6nuS1m2EfICA2dMI4duNfgdz4TX3g-kUI6IBaQvTDVxZZ8clTTnPe8SARSCAde1kLw9-Un_f09Tg8P_r2EJ3Clf7A7SAbbw52HcBXF1W8yk1ZgeVrO7CO4pE-nk6p8XMs1g8Pzlo0fO6iNDA |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3bbtQwEB2VLap44X4JFDAIJF7CZp2bjYRQL6x21XaJSkHlKSS2Q1cqSUl2i_ol_Atfx0wuCysub33gLYojy3HOjI_HkzMAT1yZBmmitM0zz7U9FRpbIi-xA51J5UnD01pK6f1uOJmIw0MZrcD37l8YSqvsfGLtqHWhKEbe55KUREgiqJ-1aRHR9vDVyRebKkjRSWtXTqOByI45-4rbt-rleBu_9VPOh68PtkZ2W2HAViRjgj4o5UEqRJomoQmFkyH_kJKbMElcf5DwNA2Vk0jt6IEIjOaZ7wXaSw3PcJlWaJrY7wVYRUru8R6sRuO96MMiwsPpVFPITs7I4f2jquTPSZ9maRGsawX8ieD-nqf5K3-uF8Dhlf956q7C5ZZ2s43GTq7Bismvw9pem1hwA75FZUEph9OKJblmdaI9bidYSeXwKKDISFKDFRmjijLzyrBjSqFnmzadfLDjMzSK4nPCWpnaik1z1kVp2L69NXoTMQp5Y4e60eulvk6nuaqdbG5esA1sm5VF9-srq4V_b8K7c5mWW9DLi9zcAYZMNvV8Fxmd1p7QfqIz7FLjFtIXWsmBBY87EMUnjTRJ3IhQ85iQFhPSLNgkeC0eIDXx-kZRfopb5xR7A0XDUIqAjKNOkeZJhRtj2k8rqS1Y74AVty6uin-iyoJHi2b8KDTvSW6KOT4jZIAUyA9DC243WF6MxBWOS3KRFogllC8Ndbklnx7VAugDJxCeFMKCZ7VB_P3149HbfU4Xd__9Cg9hDU0i3h1Pdu7BJbRct0lZWoferJyb-3BRnc6mVfmgNXIGH8_bOH4AGcqXWw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prognosis+and+complete+remission+rate+of+diffuse+large+B-cell+lymphoma+patients+in+standard+R-CHOP+with+reduction+of+vincristine%3A+A+retrospective+study&rft.jtitle=Health+science+reports&rft.au=Riasi%2C+Fatemeh&rft.au=Sajjad+Ataei+Azimi&rft.au=Allahyari%2C+Abolghasem&rft.au=Mohammad+Moeini+Nodeh&rft.date=2023-12-01&rft.pub=John+Wiley+%26+Sons%2C+Inc&rft.eissn=2398-8835&rft.volume=6&rft.issue=12&rft_id=info:doi/10.1002%2Fhsr2.1716&rft.externalDBID=HAS_PDF_LINK |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2398-8835&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2398-8835&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2398-8835&client=summon |